Compare LOAN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | IVVD |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 692.7M |
| IPO Year | 1999 | 2021 |
| Metric | LOAN | IVVD |
|---|---|---|
| Price | $4.86 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 40.8K | ★ 12.4M |
| Earning Date | 10-24-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $7,138,128.00 | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | $4.47 | $171.40 |
| P/E Ratio | $10.54 | ★ N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $4.29 | $0.35 |
| 52 Week High | $6.05 | $3.07 |
| Indicator | LOAN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 54.13 |
| Support Level | $4.64 | $2.15 |
| Resistance Level | $4.94 | $2.59 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 88.79 | 50.50 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.